BAKER BROS. ADVISORS LP — SEC Form 4 filings
SEC reporting owner CIK 1263508. 90 Form 4 filings on record with FilingPulse; latest filed 2026-08-11.
Transaction summary — filings shown
Covers the 50 most recent of 90 filings on record, filed 2025-04-02 to 2026-08-11. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 80 legs across 8 filings — 5,812,703 shares, $334,448,702 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 10 legs across 3 filings — 3,841,406 shares, $319,068,703 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 114.
- Largest priced transaction: sale of 2,838,632 shares @ $102.50 ($290,959,780) in Celcuity Inc., filed 2026-07-16.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Celcuity Inc. (CELC) | — | 2 | 4 legs · 170,100 sh · $9,571,319 | 2 legs · 3,100,000 sh · $317,750,000 | — |
| Kymera Therapeutics, Inc. (KYMR) | Director, 10% owner | 4 | 4 legs · 2,661,313 sh · $201,341,918 | — | 6 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | Director | 4 | 54 legs · 165,683 sh · $61,921,024 | — | 8 |
| Kodiak Sciences Inc. (KOD) | Director, 10% owner | 3 | 2 legs · 2,608,696 sh · $60,000,008 | — | 4 |
| Entrada Therapeutics, Inc. (TRDA) | 10% owner | 2 | 16 legs · 206,911 sh · $1,614,433 | — | — |
| KALA BIO, Inc. (KALA) | — | 1 | — | 4 legs · 730,408 sh · $1,056,722 | — |
| BeOne Medicines Ltd. (ONC) | Director | 3 | — | 4 legs · 10,998 sh · $261,981 | 6 |
| INCYTE CORP (INCY) | Director, 10% owner | 9 | — | — | 24 |
| Denali Therapeutics Inc. (DNLI) | Director | 3 | — | — | 10 |
| vTv Therapeutics Inc. (VTVT) | Director | 3 | — | — | 10 |
+9 more issuers among the filings shown — every filing appears in the table below.
Form 4 filings — BAKER BROS. ADVISORS LP
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-11 | 4 | Replimune Group, Inc. (REPL) jointly with Baker Bros. Advisors (GP) LLC, 667, L.P., Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Purchase (P): 126,394 (derivative) @ $12.06 · Purchase (P): 2,609,946 (derivative) @ $12.06 | EDGAR |
| 2026-07-16 | 4 | Celcuity Inc. (CELC) jointly with Baker Bros. Advisors (GP) LLC, BAKER FELIX, BAKER JULIAN | Sale (S): 261,368 @ $102.50 · Sale (S): 2,838,632 @ $102.50 | EDGAR |
| 2026-07-02 | 4 | INCYTE CORP (INCY) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Grant/award (A): 400 @ $0 · Grant/award (A): 400 @ $0 | EDGAR |
| 2026-07-02 | 4 | Kodiak Sciences Inc. (KOD) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Grant/award (A): 17,731 (derivative) @ $0 · Grant/award (A): 17,731 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | vTv Therapeutics Inc. (VTVT) jointly with 667, L.P., Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN, Baker Bros. Advisors (GP) LLC | Grant/award (A): 6,000 (derivative) @ $0 · Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2026-06-25 | 4 | Kymera Therapeutics, Inc. (KYMR) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Grant/award (A): 6,068 (derivative) @ $0 · Grant/award (A): 6,068 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | MADRIGAL PHARMACEUTICALS, INC. (MDGL) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Grant/award (A): 908 @ $0 · Grant/award (A): 908 @ $0 · Grant/award (A): 1,532 (derivative) @ $0 · Grant/award (A): 1,532 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | BeOne Medicines Ltd. (ONC) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Grant/award (A): 18,980 @ $0 · Grant/award (A): 18,980 @ $0 | EDGAR |
| 2026-06-10 | 4 | INCYTE CORP (INCY) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Grant/award (A): 1,642 @ $0 · Grant/award (A): 1,642 @ $0 · Grant/award (A): 6,111 (derivative) @ $0 · Grant/award (A): 6,111 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Prelude Therapeutics Inc (PRLD) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Grant/award (A): 38,000 (derivative) @ $0 · Grant/award (A): 38,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Denali Therapeutics Inc. (DNLI) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Grant/award (A): 6,408 @ $0 · Grant/award (A): 6,408 @ $0 · Grant/award (A): 19,226 (derivative) @ $0 · Grant/award (A): 19,226 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | ACADIA PHARMACEUTICALS INC (ACAD) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Grant/award (A): 18,622 @ $0 · Grant/award (A): 18,622 @ $0 · Grant/award (A): 32,008 (derivative) @ $0 · Grant/award (A): 32,008 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Grant/award (A): 6,078 @ $0 · Grant/award (A): 6,078 @ $0 · Grant/award (A): 36,474 (derivative) @ $0 · Grant/award (A): 36,474 (derivative) @ $0 | EDGAR |
| 2026-05-27 | 4 | BeOne Medicines Ltd. (ONC) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Sale (S): 2,743 @ $23.85 · Sale (S): 2,743 @ $23.85 · Sale (S): 2,756 @ $23.79 · Sale (S): 2,756 @ $23.79 | EDGAR |
| 2026-05-22 | 4 | TScan Therapeutics, Inc. (TCRX) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Grant/award (A): 67,000 (derivative) @ $0 · Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2026-05-11 | 4 | INCYTE CORP (INCY) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Option exercise (M): 15,000 @ $84.53 · Option exercise (M): 15,000 @ $84.53 · Option exercise (M): 15,000 (derivative) @ $0 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | Prelude Therapeutics Inc (PRLD) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Purchase (P): 114,601 (derivative) @ $4.44 · Purchase (P): 2,137,651 (derivative) @ $4.44 | EDGAR |
| 2026-04-07 | 4 | Replimune Group, Inc. (REPL) jointly with Baker Bros. Advisors (GP) LLC, 667, L.P., Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Grant/award (A): 44,500 (derivative) @ $0 · Grant/award (A): 44,500 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | INCYTE CORP (INCY) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Grant/award (A): 421 @ $0 · Grant/award (A): 421 @ $0 | EDGAR |
| 2026-01-14 | 4 | DBV Technologies S.A. (DBVT) jointly with Baker Bros. Advisors (GP) LLC, 667, L.P., Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Option exercise (M): 2,299,656 (derivative) @ $0 · Option exercise (M): 25,005,240 (derivative) @ $0 · Option exercise (M): 2,299,656 (derivative) @ $0 · Option exercise (M): 25,005,240 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | BICYCLE THERAPEUTICS PLC (BCYC) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Grant/award (A): 19,000 @ $0 · Grant/award (A): 19,000 @ $0 · Grant/award (A): 38,000 (derivative) @ $0 · Grant/award (A): 38,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | INCYTE CORP (INCY) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Grant/award (A): 328 @ $0 · Grant/award (A): 328 @ $0 | EDGAR |
| 2025-12-19 | 4 | Kodiak Sciences Inc. (KOD) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Purchase (P): 217,428 @ $23 · Purchase (P): 2,391,268 @ $23 | EDGAR |
| 2025-12-15 | 4 | Denali Therapeutics Inc. (DNLI) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Purchase (P): 190,523 (derivative) @ $17.49 · Purchase (P): 2,095,191 (derivative) @ $17.49 | EDGAR |
| 2025-12-11 | 4 | Kymera Therapeutics, Inc. (KYMR) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Purchase (P): 167,192 @ $86 · Purchase (P): 1,838,621 @ $86 | EDGAR |
| 2025-11-24 | 4 | Entrada Therapeutics, Inc. (TRDA) jointly with Baker Bros. Advisors (GP) LLC, BAKER FELIX, BAKER JULIAN | Purchase (P): 1,213 @ $9.07 · Purchase (P): 13,386 @ $9.07 · Purchase (P): 1,186 @ $9.07 · Purchase (P): 13,082 @ $9.07 | EDGAR |
| 2025-11-12 | 4 | Entrada Therapeutics, Inc. (TRDA) jointly with Baker Bros. Advisors (GP) LLC, BAKER FELIX, BAKER JULIAN | Purchase (P): 2,296 @ $7.21 · Purchase (P): 25,364 @ $7.21 · Purchase (P): 267 @ $7.22 · Purchase (P): 2,947 @ $7.22 · Purchase (P): 1,059 @ $7.39 · Purchase (P): 11,701 @ $7.39 · +6 more | EDGAR |
| 2025-10-02 | 4 | INCYTE CORP (INCY) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Grant/award (A): 388 @ $0 · Grant/award (A): 388 @ $0 | EDGAR |
| 2025-10-02 | 4 | KALA BIO, Inc. (KALA) jointly with Baker Bros. Advisors (GP) LLC, BAKER FELIX, BAKER JULIAN | Sale (S): 21,376 @ $1.60 · Sale (S): 195,425 @ $1.60 · Sale (S): 50,640 @ $1.38 · Sale (S): 462,967 @ $1.38 | EDGAR |
| 2025-09-10 | 4 | Celcuity Inc. (CELC) jointly with Baker Bros. Advisors (GP) LLC, BAKER FELIX, BAKER JULIAN | Purchase (P): 13,976 @ $56.22 · Purchase (P): 151,524 @ $56.22 · Purchase (P): 388 @ $58.02 · Purchase (P): 4,212 @ $58.02 | EDGAR |
| 2025-09-05 | 4 | vTv Therapeutics Inc. (VTVT) jointly with 667, L.P., Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN, Baker Bros. Advisors (GP) LLC | Grant/award (A): 4,308 · Grant/award (A): 46,692 · Grant/award (A): 217,144 (derivative) · Grant/award (A): 2,353,913 (derivative) · Grant/award (A): 221,452 (derivative) · Grant/award (A): 2,400,605 (derivative) | EDGAR |
| 2025-08-20 | 4 | MADRIGAL PHARMACEUTICALS, INC. (MDGL) jointly with Baker Bros. Advisors (GP) LLC, BAKER FELIX, BAKER JULIAN, 667, L.P., Baker Brothers Life Sciences LP | Purchase (P): 177 @ $353.88 · Purchase (P): 1,923 @ $353.88 · Purchase (P): 84 @ $355 · Purchase (P): 916 @ $355 · Purchase (P): 767 @ $357.02 · Purchase (P): 8,328 @ $357.02 · +22 more | EDGAR |
| 2025-08-20 | 4 | MADRIGAL PHARMACEUTICALS, INC. (MDGL) jointly with Baker Bros. Advisors (GP) LLC, BAKER FELIX, BAKER JULIAN, 667, L.P., Baker Brothers Life Sciences LP | Purchase (P): 2,460 @ $372.87 · Purchase (P): 26,704 @ $372.87 · Purchase (P): 675 @ $374.43 · Purchase (P): 7,325 @ $374.43 · Purchase (P): 480 @ $380.44 · Purchase (P): 5,209 @ $380.44 · +20 more | EDGAR |
| 2025-08-18 | 4 | IGM Biosciences, Inc. (IGMS) jointly with 667, L.P., Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN, Baker Bros. Advisors (GP) LLC | Code (U): 357,048 · Code (U): 3,763,362 · Code (U): 834,707 (derivative) @ $0 · Code (U): 9,886,217 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | Kodiak Sciences Inc. (KOD) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Grant/award (A): 40,000 (derivative) @ $0 · Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | TScan Therapeutics, Inc. (TCRX) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Grant/award (A): 67,000 (derivative) @ $0 · Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | INCYTE CORP (INCY) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Grant/award (A): 492 @ $0 · Grant/award (A): 492 @ $0 | EDGAR |
| 2025-07-02 | 4 | IGM Biosciences, Inc. (IGMS) jointly with 667, L.P., Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN, Baker Bros. Advisors (GP) LLC | Grant/award (A): 953 @ $0 · Grant/award (A): 953 @ $0 | EDGAR |
| 2025-06-30 | 4 | Kymera Therapeutics, Inc. (KYMR) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Purchase (P): 55,191 @ $44 · Purchase (P): 600,309 @ $44 · Purchase (P): 55,191 (derivative) @ $44.00 · Purchase (P): 600,309 (derivative) @ $44.00 | EDGAR |
| 2025-06-26 | 4 | Kymera Therapeutics, Inc. (KYMR) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Grant/award (A): 16,000 (derivative) @ $0 · Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-06-24 | 4 | MADRIGAL PHARMACEUTICALS, INC. (MDGL) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Grant/award (A): 1,430 @ $0 · Grant/award (A): 1,430 @ $0 · Grant/award (A): 2,580 (derivative) @ $0 · Grant/award (A): 2,580 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Prelude Therapeutics Inc (PRLD) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Grant/award (A): 76,000 (derivative) @ $0 · Grant/award (A): 76,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | vTv Therapeutics Inc. (VTVT) jointly with 667, L.P., Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN, Baker Bros. Advisors (GP) LLC | Grant/award (A): 4,000 (derivative) @ $0 · Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | INCYTE CORP (INCY) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Grant/award (A): 2,518 @ $0 · Grant/award (A): 2,518 @ $0 · Grant/award (A): 9,216 (derivative) @ $0 · Grant/award (A): 9,216 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Denali Therapeutics Inc. (DNLI) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Grant/award (A): 10,565 @ $0 · Grant/award (A): 10,565 @ $0 · Grant/award (A): 31,695 (derivative) @ $0 · Grant/award (A): 31,695 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Grant/award (A): 8,397 @ $0 · Grant/award (A): 8,397 @ $0 · Grant/award (A): 50,394 (derivative) @ $0 · Grant/award (A): 50,394 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | ACADIA PHARMACEUTICALS INC (ACAD) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Grant/award (A): 16,214 @ $0 · Grant/award (A): 16,214 @ $0 · Grant/award (A): 27,586 (derivative) @ $0 · Grant/award (A): 27,586 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | BeiGene, Ltd. (ONC) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Grant/award (A): 21,970 @ $0 · Grant/award (A): 21,970 @ $0 · Grant/award (A): 45,500 (derivative) @ $0 · Grant/award (A): 45,500 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Immunocore Holdings plc (IMCR) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Grant/award (A): 26,198 (derivative) @ $0 · Grant/award (A): 26,198 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4 | INCYTE CORP (INCY) jointly with 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Grant/award (A): 487 @ $0 · Grant/award (A): 487 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1263508 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →